Current Research Studies

Cancer - APEC1621A: NCI-COG Pediatric MATCH (Molecular Analysis for Therapy Choice)- Phase 2 Subprotocol of LOXO-101 (Larotrectinib) in Patients with Tumors Harboring Actionable NTRK Fusions

Condition or Therapy:

Recurrent or refractory solid tumors, non-Hodgkin lymphomas, histiocytoses and central nervous system (CNS) tumors harboring NTRK gene fusion proteins


Cancer and Blood Disorders Center, Ben Towne Center for Childhood Cancer Research

What is the goal of this study?

The goal of this study is to answer the following question: what is the complete and partial response rate in pediatric patients who have advanced solid tumors, non-Hodgkin lymphomas, or histiocytic disorders with NTRK fusions. We will also estimate the remission rates with this treatment and look at how eligible children tolerate the protocol treatment.

Who can join the study?

This study may be a good fit for children and young adults who:

  • Are ≥12 months and ≤21 years of age
  • Have a measurable disease
  • Have a NTRK gene fusion mutation

What will happen if my child takes part in this study?

If you choose to participate in this study:

  • You will take the study drug daily and keep track in a diary

Who can I contact for more information?

Please email Angela Bleeker or call the study team at (206) 987-2106 

Study Location(s):

Seattle Children's Hospital Campus

Principal Investigator:

Dr. Sarah Leary